Atrasentan Completed Phase 3 Trials for Endothelial Dysfunction Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00271492Correlation of Endothelial Function and Early Coronary Artery Disease in Humans